Abstract
Homologous recombination deficiency (HRD), characterized by tumor genomic instability, frequently occurs due to alterations in BRCA1/2. HRD has been described in non-small cell lung cancer (NSCLC), but its biological and clinical relevance in NSCLC remains unclear. Recent evidence suggests genomic instability due to HRD may alter tumor immunogenicity and predict response to immune checkpoint inhibitors (ICI), highlighting the utility of screening pathogenic BRCA1/2 alterations in NSCLC. Here, we examine the use of an ultrasensitive next-generation sequencing (NGS) liquid biopsy assay in the molecular analysis of pathogenic BRCA1/2 alterations in metastatic lung adenocarcinomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
